Constellium NV (NYSE:CSTM):
The company’s RSI reading has hit 43.31. The stock edged lower by -5.93% to close previous trading session at USD 4.76.
The shares of the company fluctuated in the range of USD 3.38 and USD 20.37 in the course of 52 weeks. Over the three months, the company’s shares have declined by -38.02% and in the past one year, it has lost -76.34%. Additionally, the stock’s year to date performance has declined -38.18%. Over the last five days its shares have surged by 4.16% and in the past six months it has moved down -40.94%.
The stock’s weekly volatility is calculated as 11.52% and monthly volatility as 11.80% with ATR of 0.64, price to cash ratio of 0.82.
Constellium NV (CSTM) on March 23, 2016 announced that the Company has priced a private offering (the “Offering”) of $425 million of U.S. dollar denominated senior secured notes due 2021 (the “Notes”). The Notes will bear interest at a rate of 7.875% per annum, payable semi-annually in arrears. The Notes will be guaranteed on a senior secured basis by certain of the Company’s subsidiaries. The Offering is expected to close on March 30, 2016, subject to customary closing conditions.
The Company intends to use a portion of the proceeds from the Offering for general corporate purposes, which may include investments in Wise Metals Intermediate Holdings LLC and its subsidiaries (“Wise Metals”) and the Company’s joint venture with UACJ Corporation
(“UACJ”), capital expenditures, repayment of debt, working capital investments, research and development efforts, or future acquisitions. Upon consummation of the Offering or shortly thereafter, the Company expects to invest €100 million of the net proceeds of the Notes in Wise Metals. There can be no assurance that the Company will successfully complete the Offering on the terms described herein or at all.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH):
The stock decreased by -5.28% to close last trading session at USD 80.74. The company’s shares oscillated in the range of USD 79.85 and USD 88.41 during intraday trade.
A total of 1.00 million shares exchanged hands, above its 3 month average volume of 958,400.00 shares. Over the last five days its shares have surged by 12.03% and in the past six months it has moved down -22.18%.
Furthermore, the stock has weekly volatility of 9.20% and monthly volatility of 8.13% with ATR of 6.81. The stock’s RSI is 68.01 and distance from 50-day simple moving average is +57.28%, whereas its distance from 20-day simple moving average is +51.82% and distance from 200-day simple moving average is -6.75%.
GW Pharmaceuticals PLC- ADR (GWPH), a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain; and Phase 2 trials in other indications, such as neuropathic pain. In addition, the companys product pipeline includes Epidiolex, a treatment for Dravet syndrome and Lennox-Gastaut syndrome, as well as other product candidates in Phase 1 and 2 clinical development for the treatment of glioma, adult epilepsy, type-2 diabetes, and schizophrenia.